From the Division of Trauma, Emergency Surgery and Surgical Critical Care, Massachusetts General Hospital, Boston, Massachusetts.
J Trauma Acute Care Surg. 2021 Jan 1;90(1):148-156. doi: 10.1097/TA.0000000000002972.
Decision making regarding the optimal timing for initiating thromboprophylaxis in patients with blunt abdominal solid organ injuries (BSOIs) remains ill-defined, with no guidelines defining optimal timing. In this study, we aimed to evaluate the relationship of the timing of thromboprophylaxis with thromboembolic and bleeding complications in the setting of BSOIs.
A retrospective analysis of the Trauma Quality Improvement Program database was performed between 2013 and 2016. All patients with isolated BSOIs (liver, spleen, pancreas, or kidney, Abbreviated Injury Scale score, <3 in other regions) who underwent initial nonoperative management (NOM) were included. Patients were divided into three groups (early, <48 hours; intermediate, 48-72 hours; and late, >72 hours) based on timing of thromboprophylaxis initiation. Primary outcomes were rates of thromboembolism and bleeding after thromboprophylaxis initiation.
Of the 25,118 patients with isolated BSOIs, 3,223 met the inclusion criteria (age, 38.7 ± 17.3 years; males, 2.082 [64.6%]), among which 1,832 (56.8%) received early thromboprophylaxis, 703 (21.8%) received intermediate thromboprophylaxis, and 688 (21.4%) received late thromboprophylaxis. Late thromboprophylaxis initiation was independently associated with a higher likelihood of both deep vein thrombosis (odds ratio [OR], 3.15; 95% confidence interval [CI], 1.68-5.91, p < 0.001) and pulmonary embolism (OR, 4.29; 95% CI, 1.95-9.42; p < 0.001). Intermediate thromboprophylaxis initiation was independently associated with a higher likelihood of deep venous thrombosis (OR, 2.38; 95% CI, 1.20-4.74; p = 0.013), but not pulmonary embolism (p = 0.960) compared with early initiation. Early (but not intermediate) thromboprophylaxis initiation was independently associated with a higher likelihood of bleeding (OR, 2.05; 95% CI, 1.11-2.18; p = 0.023), along with a history of diabetes mellitus, splenic, and high-grade liver injuries.
Early thromboprophylaxis should be considered in patients with BSOIs undergoing nonoperative management who are at low likelihood of bleeding. An intermediate delay (48-72 hours) of thromboprophylaxis should be considered for patients with diabetes mellitus, splenic injuries, and Grades 3 to 5 liver injuries.
Therapeutic, Level IV.
对于钝性腹部实质性器官损伤(BSOI)患者,启动抗血栓形成治疗的最佳时机仍未明确,目前尚无指南定义最佳时机。本研究旨在评估 BSOI 患者抗血栓形成治疗时机与血栓栓塞和出血并发症之间的关系。
对 2013 年至 2016 年创伤质量改进计划数据库进行回顾性分析。所有接受初始非手术治疗(NOM)的孤立性 BSOI(肝脏、脾脏、胰腺或肾脏,损伤严重程度评分<3 分的其他部位)患者均纳入本研究。根据抗血栓形成治疗的启动时间,患者被分为三组(早期,<48 小时;中期,48-72 小时;晚期,>72 小时)。主要结局是抗血栓形成治疗后血栓栓塞和出血的发生率。
在 25118 例孤立性 BSOI 患者中,有 3223 例符合纳入标准(年龄 38.7±17.3 岁;男性 2082[64.6%]),其中 1832 例(56.8%)接受了早期抗血栓形成治疗,703 例(21.8%)接受了中期抗血栓形成治疗,688 例(21.4%)接受了晚期抗血栓形成治疗。晚期抗血栓形成治疗的启动与深静脉血栓形成(优势比[OR],3.15;95%置信区间[CI],1.68-5.91,p<0.001)和肺栓塞(OR,4.29;95%CI,1.95-9.42;p<0.001)的发生风险增加独立相关。与早期治疗相比,中期抗血栓形成治疗的启动与深静脉血栓形成(OR,2.38;95%CI,1.20-4.74;p=0.013)的发生风险增加独立相关,但与肺栓塞(p=0.960)无关。与早期治疗相比,早期(而非中期)抗血栓形成治疗的启动与出血(OR,2.05;95%CI,1.11-2.18;p=0.023)的发生风险增加独立相关,且与糖尿病史、脾损伤和高等级肝损伤相关。
对于接受非手术治疗且出血风险较低的 BSOI 患者,应考虑早期抗血栓形成治疗。对于患有糖尿病、脾损伤和 3-5 级肝损伤的患者,可考虑延迟 48-72 小时开始抗血栓形成治疗。
治疗性,IV 级。